Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

Pfizer Inc. (NYSE:PFE) Q2 2024 Earnings Conference Call July 30, 2024 10:30 AM ETCompany ParticipantsFrancesca DeMartino – Chief Investor Relations Officer ...

Pfizer Q2 2022 Earnings Report Recap. ... PFE Outlook and Stock Performance . Pfizer affirmed its FY 2022 guidance for Comirnaty and Paxlovid revenue of roughly $32 billion and $22 billion, ...

Pfizer missed first quarter earnings Thursday amid a volatile macro environment. ... Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3.

Pfizer (PFE) came out with quarterly earnings of $0.67 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $2.04 per share a year ago.

Pfizer (PFE) reported Q2 results that exceeded estimates. The pharmaceutical and biotech major reported adjusted diluted earnings of $0.60 per share in the second quarter, a decline of 11% year ...

Pfizer Inc. (NYSE:PFE) Q2 2023 Results Conference Call August 1, 2023 10:00 AM ETCompany ParticipantsChris Stevo - SVP and Chief IR OfficerDr.

Pfizer missed first quarter earnings Thursday amid a volatile macro environment. ... Pfizer reaffirmed its 2025 outlook of $61 to $64 billion in revenue and adjusted earnings per share of $2.80 to $3.